Design Therapeutics, Inc.

DSGNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1807120

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$226.0K
Research and Development Expense	$44.4M	$57.1M	$48.6M	$24.8M	$6.1M
Operating Expenses	$62.4M	$78.2M	$67.6M	$35.8M	$8.6M
Operating Income (Loss)	-$62.4M	-$78.2M	-$67.6M	-$35.8M	-$8.3M
Other Nonoperating Income (Expense)	—	—	$4.3M	$298.0K	$50.0K
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$49.6M	-$66.9M	-$63.3M	-$35.5M	-$8.3M
Earnings Per Share, Basic	-$0.88	-$1.19	-$1.14	-$0.77	—
Earnings Per Share, Diluted

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$252.1M	$289.6M	$341.1M	$390.6M	$36.5M
Assets, Current	$248.0M	$284.6M	$335.1M	$385.4M	$36.2M
Cash and Cash Equivalents, at Carrying Value	$22.6M	$21.2M	$26.5M	$298.6M	$2.4M
Liabilities	$10.0M	$12.0M	$13.8M	$8.4M	$2.5M
Liabilities, Current	$8.5M	$9.6M	$10.8M	$5.3M	$2.3M
Accounts Payable, Current	$2.2M	$1.9M	$3.0M	$1.6M	$1.4M
Stockholders' Equity Attributable to Parent	$277.7M	$327.3M	$382.1M	-$11.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$43.1M	-$58.6M	-$51.3M	-$29.4M	-$8.7M
Net Cash Provided by (Used in) Investing Activities	$44.0M	$52.5M	-$221.0M	-$53.6M	-$33.6M
Net Cash Provided by (Used in) Financing Activities	$513.0K	$724.0K	$235.0K	$379.2M	$44.5M
Payments to Acquire Property, Plant, and Equipment	$340.0K	$256.0K	$918.0K	$1.5M	$76.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)